Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis.

The company's lead product, MM-II, is a patent-protected intra-articular biolubricant injection for the treatment of mild to moderate symptomatic knee osteoarthritis.MM-II consists of proprietary liposomes whose structure facilitates cartilage surface gliding, thus reducing pain and preventing further wear and friction that can lead to joint damage.

MM-II has demonstrated its ability to reduce osteoarthritic pain in a double-blind, randomized controlled trial conducted at Hadassah Medical Center, Israel.In 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal to further develop MM-II.

Moebius Medical conducts the requisite preclinical studies and assumes responsibility for product development and manufacturing through the end of phase 2 studies.

Sun Pharma assumes responsibility for clinical studies, regulatory submissions, and product commercialization.In December 2020, the FDA cleared the company's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II.